Consensus $8.21. Raises FY25 revenue view to up 5.7%-8.2% from up 1%-3.5%. The company said, “The Company is updating its full-year 2025 reported revenue guidance to include the Paragon 28, Inc. acquisition and currency expectations, and full-year 2025 adjusted earnings per share guidance to include Paragon 28, currency and the impact from current tariff proposals.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Is ZBH a Buy, Before Earnings?
- Notable companies reporting before Monday’s open
- Zimmer Biomet Holdings: Hold Rating Justified by Stabilized Orthopedic Volumes and Cautious Margin Outlook
- Zimmer Biomet Holdings: Strategic Product Launches and Favorable Valuation Drive Buy Rating
- Zimmer Biomet’s Strategic Acquisition of Paragon 28: Balancing Growth Potential with Execution Risks